| 曲范杰,刘 宇,孔 研.培美曲塞联合卡铂一线治疗晚期非小细胞肺癌临床分析[J].中国肿瘤,2013,22(3):235-237. |
| 培美曲塞联合卡铂一线治疗晚期非小细胞肺癌临床分析 |
| Clinical Study of Pemetrexed Combined with Carboplatin in the First-line Treatment for Advanced Non-small Cell Lung Cancer |
| 投稿时间：2012-11-27 |
| DOI：10.11735/j.issn.1004-0242.2013.03.A2012342 |
|
 |
| 中文关键词: 培美曲塞 卡铂 非小细胞肺癌 化疗 |
| 英文关键词:pemetrexed carboplatin non-small cell lung cancer chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 2453 |
| 全文下载次数: 1169 |
| 中文摘要: |
| 摘 要:［目的］ 观察和评价培美曲塞联合卡铂一线治疗晚期非小细胞肺癌的疗效和不良反应。［方法］ 将收集的29例晚期非小细胞肺癌患者采用培美曲塞联合卡铂(PC方案)作为一线化疗方案。2个周期化疗后进行疗效、不良反应评价。［结果］患者的近期有效率、中位无进展生存期（PFS）、中位生存期及1年生存率分别为44.8%、6.3个月、10.1个月及45.8%。主要不良反应是骨髓抑制、脱发、皮疹及消化道反应，但均可以耐受。［结论］ 培美曲塞联合卡铂(PC方案)一线治疗晚期非小细胞肺癌有较好的近期疗效，不良反应可耐受。 |
| 英文摘要: |
| Abstract: ［Purpose］ To investigate the efficacy and side effects of pemetrexed combined with carboplatin in the first-line treatment for advanced non-small cell lung cancer. ［Methods］ Twenty-nine patients with advanced non-small cell lung cancer were enrolled and treated with pemetrexed plus carboplatin (PC regimen). The efficacy and side effects were evaluated after 2 cycles of chemotherapy. ［Results］ The response rate， progress-free-survival(PFS)， median survival time(MST) and 1-year survival rate were 44.8%， 6.3 months，10.1 months and 45.8%， respectively. The main side effects were bone marrow suppression， alopecia， skin eruption and gastrointestinal toxicity， but they were tolerable. ［Conclusion］ Pemetrexed plus carboplatin in the first-line treatment for advanced non-small cell lung cancer is effective， safe and tolerable. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|